Tetra Radar · FDA Approvals · Decision date
Royalty Pharma plc: FDA decision date
Royalty Pharma plc (RPRX) · 25 August 2026
In April 2026, Jazz Pharmaceuticals announced that the FDA accepted for filing a supplemental BLA for Ziihera, in combination regimens for the first‑line treatment of adult patients with HER2‑positive metastatic gastroesophageal adenocarcinoma, and granted Priority Review, with a Prescription Drug User Fee Act (“PDUFA”) date of August 25, 2026.
Source: 10-Q of 5 August 2026
The date has passed; Tetra Radar has not recorded an approval.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.